AZ makes $6.9bn play for Daiichi Sankyo HER2 drug

The ADC has picked up a breakthrough designation from the FDA as treatment for advanced HER2-positive breast cancer who have previously been treated with Roche’s other HER2 drugs Herceptin ... That is however well behind the $7bn and $2.8bn added to

Gene Genie

In innovative companies, the wheels are already turning. Roche has opened Herceptin markets in China by working with insurance companies.

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

The breakthrough is thanks to a Roche discount on Perjeta – but most especially because of the arrival of cheaper Herceptin (trastuzumab) biosimilars, which have brought down the cost of combination treatment ... Herceptin sales reached $6.94bn last

Roche submits Kadcyla for FDA Real-Time review

It combines two anti-cancer properties, trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1, which it licensed from biotech ImmunoGen. ... Expanding Kadcyla's use will help Roche offset Herceptin biosimilars in the US, where

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]